#VisualAbstract: Camrelizumab plus gemcitabine and cisplatin improves progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
1. Adjuvant capecitabine resulted in fewer instances of disease recurrence and death compared to standard therapy. 2. Overall and failure-free ...
Click to read the study in The Lancet Oncology.
1. Intensity-modulated proton therapy was associated with fewer adverse events than intensity-modulated radiation therapy in the treatment of patients with ...
Click to read the study in Clinical Cancer Research.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in Lancet Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.